Prelude Therapeutics, Inc. PRLD 深 滬
等待開盤 05-01 09:30:00 美东时间
4.95
+0.680
+15.93%
華盛通- 最 高5.00
- 今 開4.52
- 成交量 27.96万股
- 最 低 4.27
- 昨 收 4.27
- 總市值 4.01亿
- 52周最高 5.54
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 0.75
- 委 比 53.37%
- 總股本 8102.03万
- 歷史最高 95.375
- 量 比 0.75
- 振 幅 17.10%
- 歷史最低 0.6101
- 每 手 1
- 風險率 1.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.
04-27 20:40
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.
04-27 19:57
Prelude Therapeutics prices $90M equity offering
Prelude Therapeutics (PRLD) has priced a public offering of more than 18M shares of its voting common stock at $4.44 each, along with pre-funded warrants for up to 2.25M additional shares at $4.4399 e...
04-20 18:38
Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share
In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price
04-20 18:32
Prelude Therapeutics Announces Presentation Of New Preclinical Data From PRT13722 For The Treatment Of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Breast Cancer, And Believes That PRT13722 Is A Highly Differentiated, First-In-Class, Orally Bioavailable, Potent And Highly-selective Kat6A Degrader
Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile.Abstract
04-20 18:11
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics announced new preclinical data for PRT13722, a first-in-class, oral KAT6A degrader targeting HR+/HER2- breast cancer. The data showed complete tumor regressions as monotherapy in multiple models, improved hematological safety, and synergy with standard therapies. PRT13722 is on track for IND filing mid-2026 and potential clinical trial initiation by year-end.
04-20 10:00
Prelude Therapeutics names Charles Morris chief medical officer
Prelude Therapeutics names Charles Morris chief medical officer Prelude Therapeutics named Charles Morris as executive vice president, chief medical officer effective April 20, 2026. Morris most recently served as chief medical officer at Lava Therapeutics. His prior roles include chief medical offi
04-15 19:30
Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company's oral KAT6A selective degrader (PRT13722) has been accepted for
03-18 04:33
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
